カテゴリ： GlobalData, アメリカ, 企業調査

Meridian Bioscience Inc (VIVO)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Meridian Bioscience Inc (VIVO) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8010977
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Meridian Bioscience Inc (Meridian) is a fully integrated life science company that carries out the development, manufacturing and distribution of diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious disease indications. It also manufactures bulk antigens, antibodies, purified reagents, nucleotides and related products for use in research and diagnostic manufacturing. Meridian develops proteins and other biological materials for use in biotechnology research for new drugs and vaccines. It offers several diagnostic tests and transport media for prenatal care, respiratory infections and organ transplant infections, among other infectious disease areas. Meridian offers its products to hospitals, clinics, veterinary testing centers, reference laboratories, research centers, physician offices and diagnostics manufacturers. The company has presence in the US, Europe, Africa and the Middle East through direct offices and subsidiaries. Meridian is headquartered in Ohio, the US.

Meridian Bioscience Inc (VIVO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Meridian Bioscience Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Meridian Bioscience Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Meridian Bioscience Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Meridian Bioscience Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Meridian Bioscience Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Meridian Bioscience Inc, Medical Equipment, Deal Details 11
Private Equity 11
Telegraph Hill Partners Acquires Dynex Technologies 11
Partnerships 12
Meridian Bioscience Enters into Licensing Agreement with University of Tennessee for Electrokinetic Sensor Technology 12
Magellan Diagnostics Enters into Distribution Agreement with Biofirm Technologies 13
Microbix Biosystems Enters into Distribution Agreement with Meridian Life Science 14
Magellan Diagnostics Enters into Distribution Agreement with MedCaptain Medical Technology 15
Biohit Enters Into Distribution Agreement With Dynex Technologies 16
Magellan Biosciences Enters Into An Agreement With Bruker 17
Magellan BioScience Enters Into An Agreement With miacom diagnostics 18
Equity Offering 19
Meridian Bioscience Plans to Raise USD100 Million in Public Offering of Securities 19
Meridian Bioscience Files Registration Statement For A Public Offering Of Securities 20
Acquisition 21
Meridian Bioscience Acquires Magellan Diagnostics for USD66 Million 21
Meridian Bioscience Acquires Minority Stake in Oasis Diagnostics 23
Thermo Fisher Scientific Acquires TREK Diagnostic Systems 24
Meridian Bioscience Inc – Key Competitors 25
Meridian Bioscience Inc – Key Employees 26
Meridian Bioscience Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Strategy And Business Planning 29
Jul 20, 2017: Meridian Announces Wholly Foreign Owned Enterprise Office in Beijing, China 29
Financial Announcements 30
Nov 09, 2017: Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance 30
Oct 19, 2017: Meridian Bioscience Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance 32
Jul 27, 2017: Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results 34
Apr 27, 2017: Meridian Bioscience Reports Second Quarter 2017 Operating Results 37
Apr 27, 2017: Meridian Bioscience Reports Second Quarter 2017 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance 39
Nov 10, 2016: Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results 41
Oct 18, 2016: Meridian Bioscience Comments on Preliminary Fiscal 2016 Operating Results and Provides Fiscal 2017 Revenue and Earnings Guidance 43
Jul 28, 2016: Meridian Bioscience Reports Third Quarter 2016 Operating Results, Declares Regular Cash Dividend, and Updates Fiscal 2016 Guidance 45
Apr 28, 2016: Meridian Bioscience Reports Second Quarter 2016 Operating Results 47
Jan 27, 2016: Meridian Bioscience Reports First Quarter 2016 Operating Results 49
Corporate Communications 51
Oct 10, 2017: Meridian Bioscience Appoints Jack Kenny as Chief Executive Officer 51
Aug 08, 2017: Meridian Bioscience Elects John Rice to the Board of Directors 52
Jul 20, 2017: Meridian Announces Wholly Foreign Owned Enterprise Office in Beijing, China 53
May 10, 2017: Meridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire 54
Legal and Regulatory 55
Oct 23, 2017: Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics 55
Jul 13, 2017: Meridian Bioscience Comments on Recent FDA Press Statement 56
Oct 03, 2016: Bioline is Certified to the ISO 13485 Quality Standard 57
Government and Public Interest 58
Jun 06, 2017: Meridian Bioscience Comments on Recent FDA Posting Related to Magellan Diagnostics 58
Product News 59
Aug 02, 2017: Bioline Launches New JetSeq Clean Kit for Next-Generation Sequencing 59
Mar 27, 2017: Bioline Launches New JetSeq DNA Quantification Kits 60
Feb 08, 2017: Bioline Launches New JetSeq DNA Library Preparation Kits 61
Feb 03, 2017: Meridian Bioscience Announces the Launch of TruQuick Rapid Tests for Asia Pacific 62
Jan 09, 2017: Bioline Launches the Full Range of EPIK miRNA Assays 63
Sep 20, 2016: Bioline Launches New SensiFAST Lyo-Ready No-ROX Mix 64
Aug 23, 2016: Meridian Bioscience Expands Its Portfolio and Launches First Analyte Specific Reagent (ASR) Products 65
Mar 03, 2016: Bioline Launches New EPIK miRNA Select Kits 66
01/26/2016: Meridian Bioscience and Lean Continuous Improvements Collaborate to Apply Lean Principles to Recent Launch of illumigene Malaria 67
01/26/2016: Meridian Bioscience and Lean Continuous Improvements, Collaborate to Apply Lean Principles to Recent Launch of illumigene Malaria 68
01/26/2016: New Malaria Test, illumigene Malaria, Sets a New Gold Standard for Diagnosis 69
Product Approvals 70
Jan 26, 2016: New Malaria Test, illumigene Malaria, Sets a New Gold Standard for Diagnosis 70
Other Significant Developments 71
Jun 30, 2017: Meridian Bioscience Comments on Recent FDA Matters Related to Magellan Diagnostics 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Meridian Bioscience Inc, Medical Equipment, Key Facts, 2016 2
Meridian Bioscience Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Meridian Bioscience Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Meridian Bioscience Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Meridian Bioscience Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Meridian Bioscience Inc, Deals By Market, 2011 to YTD 2017 9
Meridian Bioscience Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Telegraph Hill Partners Acquires Dynex Technologies 11
Meridian Bioscience Enters into Licensing Agreement with University of Tennessee for Electrokinetic Sensor Technology 12
Magellan Diagnostics Enters into Distribution Agreement with Biofirm Technologies 13
Microbix Biosystems Enters into Distribution Agreement with Meridian Life Science 14
Magellan Diagnostics Enters into Distribution Agreement with MedCaptain Medical Technology 15
Biohit Enters Into Distribution Agreement With Dynex Technologies 16
Magellan Biosciences Enters Into An Agreement With Bruker 17
Magellan BioScience Enters Into An Agreement With miacom diagnostics 18
Meridian Bioscience Plans to Raise USD100 Million in Public Offering of Securities 19
Meridian Bioscience Files Registration Statement For A Public Offering Of Securities 20
Meridian Bioscience Acquires Magellan Diagnostics for USD66 Million 21
Meridian Bioscience Acquires Minority Stake in Oasis Diagnostics 23
Thermo Fisher Scientific Acquires TREK Diagnostic Systems 24
Meridian Bioscience Inc, Key Competitors 25
Meridian Bioscience Inc, Key Employees 26
Meridian Bioscience Inc, Other Locations 27
Meridian Bioscience Inc, Subsidiaries 27

★海外企業調査レポート[Meridian Bioscience Inc (VIVO)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Freshfields Bruckhaus Deringer LLP：企業の戦略・SWOT・財務情報
    Freshfields Bruckhaus Deringer LLP - Strategy, SWOT and Corporate Finance Report Summary Freshfields Bruckhaus Deringer LLP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Barracuda Networks, Inc.：企業の戦略・SWOT・財務情報
    Barracuda Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Barracuda Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bajaj Corp Limited
    Bajaj Corp Limited - Strategy, SWOT and Corporate Finance Report Summary Bajaj Corp Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • AIM Health Group Inc：企業の戦略的SWOT分析
    AIM Health Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Aeterna Zentaris Inc (AEZS)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company’s lead product, macimorelin, a ghrelin receptor agonist and orally-ac …
  • Novant Health Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Novant Health Inc (Novant Health) is a not-for-profit, integrated healthcare service provider. The organization provides services related to assisted living, blood services, breast health, children’s services, laboratory services, emergency, laboratory services, cancer, urgent care, hospice …
  • Brake Bros Foodservice Limited：企業の戦略・SWOT・財務分析
    Brake Bros Foodservice Limited - Strategy, SWOT and Corporate Finance Report Summary Brake Bros Foodservice Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Genoptix Inc：医療機器：M&Aディール及び事業提携情報
    Summary Genoptix Inc (Genoptix) is a hematopathology center which provides oncology diagnostics and informatics services specializing in hematology and solid tumors. The center offers biopharma and healthcare laboratory, discovery, drug development, care and cost development, and patient services. G …
  • Stemline Therapeutics Inc (STML)：製薬・医療：M&Aディール及び事業提携情報
    Summary Stemline Therapeutics Inc (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pi …
  • Reliance Communications Limited：企業の戦略・SWOT・財務分析
    Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Hoerbiger Holding AG：企業の戦略的SWOT分析
    Hoerbiger Holding AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mears Group PLC (MER)：企業の財務・戦略的SWOT分析
    Summary Mears Group PLC (Mears) is a housing and social care provider. The company offers repairs, rapid response and planned maintenance services for a portfolio of social homes. It provides housing services such as new homes, energy services, housing management, home improvement, branches, planned …
  • Carillion plc：戦略・SWOT・企業財務分析
    Carillion plc - Strategy, SWOT and Corporate Finance Report Summary Carillion plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Vermillion Inc (VRML)：医療機器：M&Aディール及び事業提携情報
    Summary Vermillion Inc (Vermillion) is a medical device company that discovers, develops and markets diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, a simple blood test …
  • Henry Schein Inc (HSIC)-製薬・医療分野：企業M&A・提携分析
    Summary Henry Schein, Inc. (Henry Schein) is a distributor of healthcare products and services. Its product and service portfolio consists of dental products, medical products, animal health products, software and technology and other value-added services. It offers generic and branded pharmaceutica …
  • Galera Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …
  • Targovax ASA (TRVX)：企業の財務・戦略的SWOT分析
    Summary Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline …
  • PharmAust Ltd (PAA)-製薬・医療分野：企業M&A・提携分析
    Summary PharmAust Ltd (PharmAust) is a drug discovery and development company which provides human and veterinary proprietary medicines to treat different types of cancers. The company provides specialized medicinal and synthetic chemistry services. It specializes in bio defense and laboratory suppo …
  • Ramaco Resources Inc. (METC)：企業の財務・戦略的SWOT分析
    Ramaco Resources Inc. (METC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Original BioMedicals Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Original BioMedicals Co Ltd (OBM) is a biotechnology company that develops new drug delivering systems to deal with unmet clinical needs in the therapeutic areas of oncology, hematology and immunology. The company’s pipeline products include A01, A02 and P01. Its pipeline product OBM-A01 is …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆